Syngenta Taps New Tech to Engineer Next-Gen Maize Beyond CRISPR

CAMBRIDGE, Mass. – March 11, 2026 – Agricultural giant Syngenta is turning to a novel genetic technology to design the next generation of maize, a move that signals a strategic shift beyond established gene-editing tools like CRISPR. Syngenta has secured a research evaluation license for the KOMbine™ platform, a proprietary technology from the Cambridge-based biotech firm KOMO Biosciences, aimed at making precision changes to the corn genome.

The collaboration, announced today, will see Syngenta assess KOMO’s integrase-based system for its potential to introduce complex genetic traits into maize. This partnership underscores a growing industry focus on developing crops with sophisticated characteristics, such as enhanced drought tolerance and nitrogen efficiency, which are critical for ensuring global food security in the face of climate change.

A New Toolkit for Crop Engineering

At the heart of the agreement is KOMO's KOMbine™ platform, a technology that represents a different approach to genome engineering. While tools like CRISPR-Cas9 are famous for their ability to make precise cuts to “edit” DNA, KOMO’s technology focuses on “gene addition” or, more accurately, the precise insertion of large genetic payloads into a plant's genome.

KOMO’s platform uses a non-viral, integrase-based system. Integrases are enzymes that can insert a piece of DNA into a specific location within a larger DNA molecule, like a chromosome. This method avoids creating double-strand breaks in the DNA, a hallmark of many nuclease-based editing systems that can sometimes lead to unintended cellular responses or off-target effects. The key advantage is its capacity to reliably install large and complex genetic circuits—multiple genes that must work in concert—into a predefined, safe location in the genome.

This capability is crucial for the next frontier of crop improvement. Many of the most sought-after traits, such as resilience to environmental stress or improved nutritional profiles, are not controlled by a single gene but by a network of them. Existing technologies can struggle to efficiently and predictably insert these large, multi-gene cassettes.

“As biological systems become more complex, the question is no longer just whether a gene can be edited, but whether genetic programs can be reliably installed and controlled,” said Jennifer Manning, Founder and CEO of KOMO Biosciences, in a statement. “KOMO was built to enable that next layer of genome engineering.”

Syngenta's Strategic Bet on Precision Agriculture

For Syngenta, a global leader in the agricultural sector, this partnership is a calculated move to expand its technological arsenal. Facing intense competition from rivals like Corteva Agriscience and Bayer Crop Science, Syngenta is actively investing in innovations that promise to deliver more sustainable and productive farming solutions. The company has already committed to investing $2 billion in breakthrough sustainable innovation by 2025.

The collaboration with KOMO allows Syngenta to explore a complementary technology to its own in-house CRISPR programs. By licensing KOMbine™, Syngenta gains access to a tool potentially better suited for the complex trait development required to address modern agricultural challenges. It reflects a broader industry trend where large agricultural corporations are forming strategic alliances with smaller, specialized biotechs to accelerate R&D and maintain a competitive edge.

“At Syngenta, we’re energized by our collaboration with KOMO Biosciences,” stated Trevor Hohls, Global Head of R&D at Syngenta Seeds. “By combining our deep expertise in plant genetics and trait introgression with KOMO’s cutting-edge technology, we can accelerate our commitment to bring more precise solutions to farmers around the world.”

Engineering Resilience for a Warmer Planet

The ultimate goal of this high-tech collaboration is grounded in one of the world's most fundamental needs: a stable and abundant food supply. Maize is one of the top three most important crops globally, serving as a staple food for billions and a primary component of animal feed and biofuels. The global maize seed market, valued at over $25 billion in 2024, is projected to exceed $40 billion by the early 2030s, driven by rising demand.

However, maize production is increasingly vulnerable to the effects of climate change. Projections show that rising temperatures, prolonged droughts, and unpredictable weather patterns could significantly reduce yields in key growing regions. Developing new maize varieties that can thrive in these challenging conditions is a top priority for agricultural scientists.

The precision offered by platforms like KOMbine™ could enable the development of crops with enhanced stress tolerance, greater yield stability, and improved resource efficiency, meaning they could require less water or fertilizer. By allowing scientists to install entire genetic pathways, the technology could unlock a new level of sophistication in crop design, leading to plants that are not just incrementally better, but fundamentally more resilient.

Navigating the Path to Market

Even the most promising technology faces hurdles on its journey from the lab to the field, particularly in the highly regulated and publicly scrutinized world of genetic modification. However, the landscape for gene-edited crops is evolving rapidly and becoming more favorable.

In the United States, the Department of Agriculture (USDA) regulates new plant varieties based on their characteristics, not the method of their creation. Many gene-edited plants that could have been produced through conventional breeding are not subject to the same stringent oversight as traditional GMOs.

More significantly, the European Union, which has historically maintained a near-total ban on GMOs, recently reached a provisional agreement to relax its rules for what it calls New Genomic Techniques (NGTs). Under the new framework, gene-edited plants deemed comparable to conventionally bred varieties would face fewer regulatory hurdles and would not require special labeling. This policy shift could open up a massive market for precisely engineered crops developed through technologies like KOMbine™.

Public perception also appears to be shifting, with greater acceptance of gene editing compared to older transgenic methods, especially when the technology is used to deliver clear benefits like improved sustainability or nutrition. The success of this new generation of crops will depend not only on scientific breakthroughs but also on transparent communication about their purpose and safety. This initial evaluation by Syngenta is a critical first step in a long process, but it points toward a future where agricultural technology is deployed with ever-increasing precision to solve our planet's most pressing challenges.